|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||18.30 - 18.50|
|52-week range||11.00 - 22.86|
|Beta (5Y monthly)||0.74|
|PE ratio (TTM)||62.93|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The gleaming white table in the boardroom of Oxford Biomedica’s headquarters is so enormous and heavy it can only be removed by taking down the windows and lifting it with a crane. The carpet feels soft, squishy – expensive.
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option to license Oxford Biomedica’s lentiviral vector technology to manufacture, register and commercialise BI 3720931, a lentiviral vector-based gene therapy for th
Most readers would already be aware that Oxford Biomedica's (LON:OXB) stock increased significantly by 11% over the...